MRD Explained | What It Means for Your CLL

As part of CLL Global Research Foundation’s virtual town hall, Dr. Jackie Broadway-Duren responded to an audience question about minimal residual disease (MRD). Dr. Broadway-Duren defines MRD and goes on to share how this testing is used in CLL patient care.

Expert Panel:

Dr. Alessandra Ferrajoli

Dr. Alessandra Ferrajoli, The University of Texas MD Anderson Cancer Center

Dr. Jackie Broadway-Duren

Dr. Jackie Broadway-Duren, The University of Texas MD Anderson Cancer Center

Transcript:

Jeff Folloder:  What is MRD? And if someone gets the good MRD rating, I’ve got another question for you. So, let’s start with that one.

Dr. Jackie Broadway-Duren:  So, MRD is an acronym for minimal residual disease. That means after you’ve had your treatment, we go back and evaluate sometimes through the blood, through peripheral, or through the bone marrow and see how much CLL remains at the completion of that course of treatment.

So, it’s measured in percentages. Ideally, we’d like to see undetectable MRD, meaning there are no markers that would identify the cells there as CLL cells, which would be reported back to your flow cytometry – CD20 and all those markers. If it’s MRD undetectable, then that’s the best outcome that we can hope for. Now, the problem with that is many patients think if it’s MRD-undetected, that means they are cured. As Dr. Ferrajoli would attest to, we can’t say that anybody is cured with CLL yet. I think it’s coming one day. But if, in fact, you have it, we try to make patients aware that it’s undetectable.

But depending on what your prognostic factors are, again, this is where they are very important. Unmutated 17P, TP53, at some point in time it’s going to resurface, so other treatments may be indicated at that time. So, that’s what MRD is. It helps guide decisions whether you’ve reached the end of this regiment, is that good enough, or do we proceed with therapy past this point. There are many other factors that help make that determination.

Jeff Folloder:  That’s very cool. Let me do a follow-up question. I had it right here in my back pocket. Assuming someone gets to this undetectable MRD status, what percentage of patients stay in remission and for how long? What does MRD-negative look like?

Dr. Jackie Broadway-Duren:  It depends on the patient. It depends on if they’re on a research protocol.

I had this situation just today that happened. The patient is MRD-negative. He’s clonal sequencing-negative. However, the patient didn’t understand why would I need to take any additional therapy? But I guess maybe Dr. Ferrajoli could chime in on this. The protocol is written that the patient will continue. I guess we can’t continue in patients who we know have poor prognostic factors. May not necessarily stop because you got an undetectable MRD on that patient. I guess it would be more like a maintenance therapy. Dr. Ferraioli, would you care to add to that?

Dr. Alessandra Ferrajoli:  Yes. So, as Jackie said, MRD really needs to be seen in the context of that individual patient. It’s mostly a tool for us physicians to anticipate our next step, our next movement.                             

If the patient has really good, favorable prognostic factor and has received a relatively intense time-limited therapy, then there is a possibility the MRD will stay undetectable in a good proportion of patients for maybe two, three years, for a prolonged period of time. But few patients, we know this from the time of the chemo immunotherapy, few patients will stay undetectable for life. If the patient is a patient that instead has some adverse prognostic factor, let’s say that this treatment is the second treatment or the third treatment.

Even if MRD negativity is achieved, is reached, then in that context, I would anticipate it will be of shorter duration. Since Jackie kindly gave me the option to chime in, it’s really important to understand that return of MRD does not mean being out of remission and does not mean that you need treatment right away. It’s really a very sophisticated tool. In fact, there are different levels for if we do MRD by flowcytometry, we can detect 1 in 10,000 cells. If we use the clone SIQ, that is the more sensitive, we can detect 1 in 1M cells.

It’s really very sophisticated tool that we physicians use to follow the disease once we have achieved, to push the disease back to a point that by just regular microscope or by regular blood count cannot be detected anymore.